Day One Biopharmaceuticals, Inc.: M&A transaction — Servier completes $2.5B acquisition of Day One Biopharma; shares to be delisted

Day One Biopharmaceuticals, Inc.

Tender offer expired with 88,180,910 shares (85.34%) validly tendered; all conditions met.
Merger completed; stockholders received $21.50 per share cash, ~$2.5B equity value.
Trading halted on Nasdaq; delisting and deregistration initiated via Form 25 and Form 15.
All prior directors and officers removed; replaced by Servier appointees David K. Lee and Danielle Button.
Company equity plans, ESPP, and at-market sales agreement terminated effective at closing.

item 1.02 item 2.01 item 3.01 item 5.01 item 5.03 item 3.03 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Day One Biopharmaceuticals, Inc.: Amended and restated certificate of incorporation effective at the Effective Time of the merger.

Change: charter amendment

Exact text from the filing

Pursuant to the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “ Amended and Restated Certificate of Incorporation ”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Day One Biopharmaceuticals, Inc.: Bylaws of Purchaser became the bylaws of the Company effective at the Effective Time.

Change: bylaw amendment

Exact text from the filing

In addition, pursuant to the Merger Agreement, as of the Effective Time, the bylaws of Purchaser, as in effect immediately prior to the Effective Time, became the bylaws of the Company (the “ Amended and Restated Bylaws ”).

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Day One Biopharmaceuticals, Inc. underwent a change of control involving Servier Pharmaceuticals LLC (Parent), Servier Detroit Inc. (Purchaser), and Servier S.A.S. (Guarantor) for $21.50 per share in cash (closed 2026-04-23).

Action: change of control
Counterparty: Servier Pharmaceuticals LLC (Parent), Servier Detroit Inc. (Purchaser), and Servier S.A.S. (Guarantor)
Consideration: $21.50 per share in cash
Closing: 2026-04-23

Exact text from the filing

tender offer (the “ Offer ”) to purchase all of the issued and outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at a price of $21.50 per share (the “ Offer Price ”), net to the seller in cash, without interest thereon, and less any applicable tax withholding, upon the terms and subject to the conditions set

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Day One Biopharmaceuticals, Inc. terminated Equity Distribution Agreement with Piper Sandler & Co. and JonesTrading Institutional Services LLC (effective 2026-04-20).

Action: termination
Agreement: atm program
Counterparty: Piper Sandler & Co. and JonesTrading Institutional Services LLC
Effective: 2026-04-20

Exact text from the filing

on April 20, 2026, the Company provided written notice to Piper Sandler & Co. and JonesTrading Institutional Services LLC as sales agents (together, the “ Agents ”), of its election to terminate the Equity Distribution Agreement, dated June 1, 2022, between the Company and the Agents (the “ Sales Agreement ”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-26-171997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.